Profile And Risk Factors of Stevens Johnson Syndrome–Toxic Epidermal Necrolysis on Adult Patients in Dr. Moewardi General Hospital Surakarta from January 2019 – December 2022

Osdatilla Esa Putri, Triasari Oktavriana, Stella Gracia Octarica, Benedikta Lauda Anandita, Sesia Pradestine, Trya Oktaviani

Abstract


Background: Steven Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are acute and life-threatening skin diseases, commonly induced by medications. Study on SJS/TEN in Indonesia was still limited, hence knowledge about the profile and risk factors of SJS/TEN patients is still required to provide appropriate management and reduce patient mortality rate. This study aimed to determine the profile and risk factors of adult SJS/TEN patients in the inpatient installation of RSDM Surakarta. Methods: We conducted a cross sectional study using secondary data from medical records of SJS/TEN patients at the inpatient installation of Dr. Moewardi hospital, Surakarta from 2019 – 2022. Correlation tests on characteristics, comorbidity with length of stay (LoS) and discharge status were analyzed. Results: Of the total 147,531 inpatients, 35 (0.02%) of them were diagnosed with SJS/TEN, dominated by females (57.14%) with the mean  of 45.74 years old.  Most subjects were diagnosed with SJS (48.57%), followed by SJS/TEN (40.0%) and TEN (11.43%). The mean LoS was  ± 8 days. Most subjects were discharged alive (85.71%). Paracetamol was the most common causative drug (25.71%), followed by cefadroxil (11.43%). Acute kidney injury (AKI) was the most common comorbidity (14.29%, p = 0.040). Spearman Rank test obtained no correlation between comorbidities and LoS (r = 0.028 ; p = 0.842) as well as discharge status (r = 0.063 ; p = 0.651). Conclusion: SJS/TEN is rare case with high mortality rate. Patients’ comorbidities have a very weak correlation with LoS and discharge status. Initial knowledge of the patient’s profile and risk factors including comorbidity and causative drugs can optimise comprehensive therapy for SJS/TEN patients.


Keywords


SJS, TEN, comorbidities, drug triggers

Full Text:

PDF

References


. Labib A, Milroy C. Toxic epidermal necrolysis. Statpearls. 2022.

. Anwar AND, Carolia N, Hamzah MS. Stevens johnson syndrome - toxic epidermal necrolisis overlap sisebabkan oleh drug eruption obat anti tuberkulosis. Medical Faculty of Lampung University. 2017;7(9):8–14.

. Oakley AM, Krishnamurthy K. Stevens-Johnson Syndrome. 2023;1–10.

. Abdulah R, Suwandiman TF, Handayani N, Destiani DP, Suwantika AA, Barliana MI, et al. Incidence, causative drugs, and economic consequences of drug-induced SJS, TEN, and SJS-TEN overlap and potential drug-drug interactions during treatment: a retrospective analysis at an Indonesian referral hospital. Ther Clin Risk Manag. 2017;13:919–25.

. Frantz R, Huang S, Are A, Motaparthi K. Stevens–johnson syndrome and toxic epidermal necrolysis: A review of diagnosis and management. Medicina (Lithuania). 2021;57(9):1–15.

. Zimmerman D, Dang NH. Stevens-johnson syndrome (SJS) and toxic epidermal necrolysis (TEN): Immunologic reactions. Oncologic Critical Care. 2019;267–80.

. Fakoya AOJ, Omenyi P, Anthony P, Anthony F, Etti P, Otohinoyi DA, et al. Stevens - Johnson syndrome and toxic epidermal necrolysis; extensive review of reports of drug-induced etiologies, and possible therapeutic modalities. Open Access Maced J Med Sci. 2018;6(4):730–8.

. Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis. 2010 Dec;5:39.

. Dewi CC. Tinjauan atas Stevens-Johnson Syndrome dan Toxic Epidermal Necrolysis. Cermin Dunia Kedokteran. 2019;46(7):55–9.

. Rahmasari AT, Indramaya DiM, Lestari P. Profile And Treatment Steven Johnson Syndrome Patients In Inpatient Kemuning I And II RSUD DR. Soetomo Period 2011-2015. Nusantara Medical Science Journal. 2019;4(2):32.

. Ezaldein H, Totonchy M, Chow C, Samuel A, Ventura A. The effect of comorbidities on overall mortality in Stevens- Johnson Syndrome: an analysis of the Nationwide Inpatient Sample. Dermatol Online J. 2017;23(4):1–7.

. Lee TH, Lee CC, Ng CY, Chang MY, Chang SW, Fan PC, et al. The influence of acute kidney injury on the outcome of Stevens–Johnson syndrome and toxic epidermal necrolysis: The prognostic value of KDIGO staging. PLoS One. 2018;13(9):1–12.

. Trivedi B, Darji N, Malhotra S, Patel P. Antiepileptic Drugs-induced Stevens-Johnson syndrome: A case Series. J Basic Clin Pharm. 2017;8(1):42.

. Hasegawa A, Abe R. Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis. F1000Res. 2020;9.

. Wolff K, Johnson RA, Saavedra AP. Fitzpatricks Color Atlas and Synopsis of Clinical Dermatology. Treatment of Skin Disease: Comprehensive Therapeutic Strategies. 2017. 448–450 p.

. Sousa-Pinto B, Araújo L, Freitas A, Correia O, Delgado L. Stevens-Johnson syndrome/toxic epidermal necrolysis and erythema multiforme drug-related hospitalisations in a national administrative database. Clin Transl Allergy. 2018;8(1):1–10.

. Duplisea MJ, Ziemer CM, Laughon SL, Williams FN. Characteristics associated with disease prevalence, SCORTEN, length of stay, and mortality in hospitalized SJS/TEN patients: A single-center, eleven-year experience. Burns Open. 2022;6(3):110–5.

. Primisawitri PP, Mawardi P. The Correlation of Neutrophil–Lymphocyte Ratio and Eosinophil Count with SCORTEN in SJS/TEN. Clin Cosmet Investig Dermatol. 2022;15(March):547–56.

. Ubukata N, Nakatani E, Hashizume H, Sasaki H, Miyachi Y. Risk factors and drugs that trigger the onset of Stevens–Johnson syndrome and toxic epidermal necrolysis: A population-based cohort study using the Shizuoka Kokuho database. JAAD Int. 2023 Jun;11:24.

. Isaac WA, Damayanti D, Fatimah N, Hidayati AN. The Profiles of Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) Patients in Tertiary Hospital. Berkala Ilmu Kesehatan Kulit dan Kelamin. 2021;33(2):116.

. Frey N, Bodmer M, Bircher A, Rüegg S, Jick SS, Meier CR, et al. The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptic drugs. Epilepsia. 2017;58(12):2178–85.

. Sangwan. Controversies in the Management of Cutaneous Adverse Drug Reactions Systemic Corticosteroids in the Management of SJS / TEN : Is it Still. Indian J Dermatol. 2018;63(2):125–30.

. Imatoh T, Saito Y. Associations Between Stevens–Johnson Syndrome and Infection: Overview of Pharmacoepidemiological Studies. Front Med (Lausanne). 2021;8(March):1–6.

. Mawson AR, Eriator I, Karre S. Stevens-johnson syndrome and toxic epidermal necrolysis (SJS/TEN): Could retinoids play a causative role? Medical Science Monitor. 2015;21:133–43.

. Lebrun-Vignes B, Guy C, Jean-Pastor MJ, Gras-Champel V, Zenut M. Is acetaminophen associated with a risk of Stevens–Johnson syndrome and toxic epidermal necrolysis? Analysis of the French Pharmacovigilance Database. Br J Clin Pharmacol. 2018;84(2):331–8.

. Queena Maureen Wijanto J, Damayanti Dr, Fathul Qorib M, Anggraeni S, Rosita Sigit Prakoeswa C. Risk Factors for Stevens Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) in Dr. Soetomo General Hospital Surabaya. International Journal of Research Publications. 2021;92(1):361–8.

. Patel TK, Barvaliya MJ, Sharma D, Tripathi C. A systematic review of the drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Indian population. Indian J Dermatol Venereol Leprol. 2013 May;79(3):389.

. Deore SS. Drug Induced - Stevens Johnson Syndrome- A Case Report.pdf - Google Drive. International Journal of Scientifi c Study. 2014;2:2–5.

. Eric. HHS Public Access Author manuscript Epilepsia. Author manuscript; available in PMC 2019 December 01. Published in final edited form as: Epilepsia. 2018 December ; 59(12): 2318–2324. doi:10.1111/epi.14591. Stevens-Johnson Syndrome and Toxic Epidermal Necro. Physiol Behav. 2017;176(5):139–48.

. Rajput R, Sagari S, Durgavanshi A, Kanwar A. Paracetamol induced Steven-Johnson syndrome: A rare case report. Contemp Clin Dent. 2015;6:S278–81.

. Ban GY, Ahn SJ, Yoo HS, Park HS, Ye YM. Stevens–johnson syndrome and toxic epidermal necrolysis associated with acetaminophen use during viral infections. Immune Netw. 2016;16(4):256–60.

. Dilokthornsakul P, Sawangjit R, Inprasong C, Chunhasewee S, Rattanapan P, Thoopputra T, et al. Healthcare utilization and cost of Stevens-Johnson syndrome and toxic epidermal necrolysis management in Thailand. J Postgrad Med. 2016;62(2):109–14.

. Hsu DY, Brieva J, Silverberg NB, Silverberg JI. Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults. Journal of Investigative Dermatology. 2016;136(7):1387–97.

. Gupta L, Martin A, Agarwal N, D’Souza P, Das S, Kumar R, et al. Guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis: An Indian perspective. Indian J Dermatol Venereol Leprol. 2016;82(6):603–25.

. Hsieh MH, Watanabe T, Aihara M. Recent Dermatological Treatments for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Japan. Front Med (Lausanne). 2021;8(July):1–9.

. Suwarsa O, Yuwita W, Dharmadji HP, Sutedja E. Stevens-Johnson syndrome and toxic epidermal necrolysis in Dr. Hasan Sadikin General Hospital Bandung, Indonesia from 2009-2013. Asia Pac Allergy. 2016;6(1):43–7.

. Matsumoto K, Ueta M, Inatomi T, Fukuoka H, Mieno H, Risa T-M, et al. Topical Betamethasone Treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis with Ocular Involvement in the Acute Phase. Am J Ophthalmol. 2023;253:142–51.

. Wilken R, Li CS, Sharon VR, Kim K, Patel FB, Patel F, et al. Topical clobetasol for the treatment of toxic epidermal necrolysis: Study protocol for a randomized controlled trial. Trials. 2015;16(1):1–10.




DOI: https://doi.org/10.33854/heme.v6i2.1517

Refbacks

  • There are currently no refbacks.


Creative Commons License   Health and Medical Journal This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.